Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model

Genesis

Volumn 49, Issue 5, 2011, Pages 392-402

  Hernández Vargas, René ^a   Fonseca Ornelas, Luis ^a   López González, Ignacio ^a   Riesgo Escovar, Juan ^b   Zurita, Mario ^a   Reynaud, Enrique ^a  

^a INSTITUTO DE BIOTECNOLOGÍA   (Mexico)

^b CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

Author keywords

Amyloid; Animal model; Lewy bodies; Neurodegenerative disease

Indexed keywords

ALPHA SYNUCLEIN; NEUROPEPTIDE; SYNPHILIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DROSOPHILA MELANOGASTER; LEWY BODY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOM; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIPARKINSON AGENTS; BLOTTING, WESTERN; CARBIDOPA; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DROSOPHILA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEVODOPA; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROTOXICITY SYNDROMES; PARKINSON DISEASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79956014439     PISSN: 1526954X     EISSN: 1526968X     Source Type: Journal    
DOI: 10.1002/dvg.20740     Document Type: Article

References (74)

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252.
2. Bandyopadhyay U, Cuervo AM. 2007. Chaperone-mediated autophagy in aging and neurodegeneration: Lessons from alpha-synuclein. Exp Gerontol 42: 120-128.
3. Borycz J, Borycz JA, Loubani M, Meinertzhagen IA. 2002. tan and ebony genes regulate a novel pathway for transmitter metabolism at fly photoreceptor terminals. J Neurosci 22: 10549-10557.
4. Botella JA, Bayersdorfer F, Gmeiner F, Schneuwly S. 2009. Modelling Parkinson's disease in Drosophila. Neuromolecular Med 11: 268-280.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
6. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. 2001. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease. Nat Med 7: 1144-1150.
7. Clements J, Lu Z, Gehring WJ, Meinertzhagen IA, Callaerts P. 2008. Central projections of photoreceptor axons originating from ectopic eyes in Drosophila. Proc Natl Acad Sci USA 105: 8968-8973.
8. Conway KA, Harper JD, Lansbury PT Jr. 2000. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39: 2552-2563.
9. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346-1349.
10. Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, Prigent A, Robinson JC, Pradier L, Ruberg M, Mirande M, Hirsch E, Rooney T, Fournier A, Brice A. 2003. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: Linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12: 1427-1437.
11. Dev KK, van der Putten H, Sommer B, Rovelli G. 2003. Part I: Parkin-associated proteins and Parkinson's disease. Neuropharmacology 45: 1-13.
12. Engelender S. 2008. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy 4: 372-374.
13. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA. 1999. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22: 110-114.
14. Eyal A, Engelender S. 2006. Synphilin isoforms and the search for a cellular model of Lewy body formation in Parkinson's disease. Cell Cycle 5: 2082-2086.
15. Eyal A, Szargel R, Avraham E, Liani E, Haskin J, Rott R, Engelender S. 2006. Synphilin-1A: An aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc Natl Acad Sci USA 103: 5917-5922.
16. Feany MB. 2010. New approaches to the pathology and genetics of neurodegeneration. Am J Pathol 176.
17. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404: 394-398.
18. Forno LS. 1996. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272.
19. Friggi-Grelin F, Coulom H, Meller M, Gomez D, Hirsh J, Birman S. 2003. Targeted gene expression in Drosophila dopaminergic cells using regulatory sequences from tyrosine hydroxylase. J Neurobiol 54: 618-627.
20. Giaime E, Sunyach C, Herrant M, Grosso S, Auberger P, McLean PJ, Checler F, da Costa CA. 2006. Caspase-3-derived C-terminal product of synphilin-1 displays antiapoptotic function via modulation of the p53-dependent cell death pathway. J Biol Chem 281: 11515-11522.
21. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
22. Giasson BI, Lee VM. 2000. A new link between pesticides and Parkinson's disease. Nat Neurosci 3: 1227-1228.
23. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ. 2002. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277: 48984-48992.
24. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. 2001. Complex I and Parkinson's disease. IUBMB Life 52: 135-141.
25. Hardy J. 2003. Impact of genetic analysis on Parkinson's disease research. Mov Disord 18 ( Suppl 6): S96-S98.
26. Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H. 2004. Functional consequences of alpha-synuclein tyrosine nitration: Diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279: 47746-47753.
27. Hsu M, Srinivas B, Kumar J, Subramanian R, Andersen J. 2005. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: Implications for Parkinson's disease. J Neurochem 92: 1091-1103.
28. Huynh DP, Nguyen DT, Pulst-Korenberg JB, Brice A, Pulst SM. 2007. Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp Neurol 203: 531-541.
29. Huynh DP, Scoles DR, Nguyen D, Pulst SM. 2003. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet 12: 2587-2597.
30. Imai Y, Soda M, Takahashi R. 2000. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275: 35661-35664.
31. Junn E, Lee SS, Suhr UT, Mouradian MM. 2002. Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 277: 47870-47877.
32. Kitao Y, Imai Y, Ozawa K, Kataoka A, Ikeda T, Soda M, Nakimawa K, Kiyama H, Stern DM, Hori O, Wakamatsu K, Ito S, Itohara S, Takahashi R, Ogawa S. 2007. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 16: 50-60.
33. Krenz A, Falkenburger BH, Gerhardt E, Drinkut A, Schulz JB. 2009. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors. J Neurochem 108: 139-146.
34. Kruger R. 2004. The role of synphilin-1 in synaptic function and protein degradation. Cell Tissue Res 318: 195-199.
35. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
36. Lang AE, Lozano AM. 1998a. Parkinson's disease. First of two parts. N Engl J Med 339: 1044-1053.
37. Lang AE, Lozano AM. 1998b. Parkinson's disease. Second of two parts. N Engl J Med 339: 1130-1143.
38. Lansbury PT Jr, Brice A. 2002. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 12: 299-306.
39. Lee G, Junn E, Tanaka M, Kim YM, Mouradian MM. 2002. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. J Neurochem 83: 346-352.
40. Lu B, Vogel H. 2009. Drosophila models of neurodegenerative diseases. Annu Rev Pathol 4: 315-342.
41. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM. 2008. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118: 777-788.
42. Marx FP, Holzmann C, Strauss KM, Li L, Eberhardt O, Gerhardt E, Cookson MR, Hernandez D, Farrer MJ, Kachergus J, Engelender S, Ross CA, Berger K, Schols L, Schulz JB, Riess O, Kruger R. 2003. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 12: 1223-1231.
43. Marx FP, Soehn AS, Berg D, Melle C, Schiesling C, Lang M, Kautzmann S, Strauss KM, Franck T, Engelender S, Pahnke J, Dawson S, von Eggeling F, Schulz JB, Riess O, Kruger R. 2007. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-Implications for Parkinson's disease. FASEB J 21: 1759-1767.
44. Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
45. Murakami T, Shoji M, Imai Y, Inoue H, Kawarabayashi T, Matsubara E, Harigaya Y, Sasaki A, Takahashi R, Abe K. 2004. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann Neurol 55: 439-442.
46. Nagel F, Bahr M, Dietz GP. 2009. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins. Brain Res Bull 79: 303-309.
47. Neckameyer W, O'Donnell J, Huang Z, Stark W. 2001. Dopamine and sensory tissue development in Drosophila melanogaster. J Neurobiol 47: 280-294.
48. Neystat M, Rzhetskaya M, Kholodilov N, Burke RE. 2002. Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neurosci Lett 325: 119-123.
49. O'Farrell C, Murphy DD, Petrucelli L, Singleton AB, Hussey J, Farrer M, Hardy J, Dickson DW, Cookson MR. 2001. Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Brain Res Mol Brain Res 97: 94-102.
50. Pirrotta V. 1988. Vectors for P-mediated transformation in Drosophila. Biotechnology 10: 437-456.
51. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
52. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, Bell SM, Combaret V, Puisieux A, Mighell AJ, Robinson PA, Inglehearn CF, Isaacs JD, Markham AF. 2003. Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 3: 18.
53. Ramsey CP, Giasson BI. 2007. Role of mitochondrial dysfunction in Parkinson's disease: Implications for treatment. Drugs Aging 24: 95-105.
54. Ribeiro CS, Carneiro K, Ross CA, Menezes JR, Engelender S. 2002. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem 277: 23927-23933.
55. Riesgo-Escovar J, Raha D, Carlson JR. 1995. Requirement for a phospholipase C in odor response: overlap between olfaction and vision in Drosophila. Proc Natl Acad Sci USA 92: 2864-2868.
56. Riesgo-Escovar JR, Jenni M, Fritz A, Hafen E. 1996. The Drosophila Jun-N-terminal kinase is required for cell morphogenesis but not for DJun-dependent cell fate specification in the eye. Genes Dev 10: 2759-2768.
57. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. 2003. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37: 583-595.
58. Sherer TB, Betarbet R, Greenamyre JT. 2001. Pesticides and Parkinson's disease. Scientific World J 1: 207-208.
59. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. 2003. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341: 87-90.
60. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302: 841.
61. Smith WW, Liu Z, Liang Y, Masuda N, Swing DA, Jenkins NA, Copeland NG, Troncoso JC, Pletnikov M, Dawson TM, Martin LJ, Moran TH, Lee MK, Borchelt DR, Ross CA. 2010. Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Hum Mol Genet 19: 2087-2098.
62. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95: 6469-6473.
63. Spillantini MG, Goedert M. 2000. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920: 16-27.
64. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH. 2000. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9: 2683-2689.
65. Takeda A, Sugeno N, Hasegawa T, Kobayashi M, Kikuchi A. 2008. Cellular pathophysiology of Parkinson's disease. Rinsho Shinkeigaku 48: 984-985.
66. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. 2004. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279: 4625-4631.
67. Tofaris GK, Spillantini MG. 2007. Physiological and pathological properties of alpha-synuclein. Cell Mol Life Sci 64: 2194-2201.
68. Uversky VN. 2003. A protein-chameleon: Conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21: 211-234.
69. Wakabayashi K, Engelender S, Tanaka Y, Yoshimoto M, Mori F, Tsuji S, Ross CA, Takahashi H. 2002. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol 103: 209-214.
70. Wakabayashi K, Engelender S, Yoshimoto M, Tsuji S, Ross CA, Takahashi H. 2000. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 47: 521-523.
71. Wakabayashi K, Takahashi H. 2007. Pathology of familial Parkinson's disease. Brain Nerve 59: 851-864.
72. Wong ES, Tan JM, Soong WE, Hussein K, Nukina N, Dawson VL, Dawson TM, Cuervo AM, Lim KL. 2008. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet 17: 2570-2582.
73. Zaarur N, Meriin AB, Gabai VL, Sherman MY. 2008. Triggering aggresome formation. Dissecting aggresome-targeting and aggregation signals in synphilin 1. J Biol Chem 283: 27575-27584.
74. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.